<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toon Braeye</style></author><author><style face="normal" font="default" size="100%">Laura Cornelissen</style></author><author><style face="normal" font="default" size="100%">Lucy Catteau</style></author><author><style face="normal" font="default" size="100%">Freek Haarhuis</style></author><author><style face="normal" font="default" size="100%">Kristiaan Proesmans</style></author><author><style face="normal" font="default" size="100%">Karin De Ridder</style></author><author><style face="normal" font="default" size="100%">Achille Djiena</style></author><author><style face="normal" font="default" size="100%">Romain Mahieu</style></author><author><style face="normal" font="default" size="100%">Frances De Leeuw</style></author><author><style face="normal" font="default" size="100%">Alex Dreuw</style></author><author><style face="normal" font="default" size="100%">Hammami, Naïma</style></author><author><style face="normal" font="default" size="100%">Sophie Quoilin</style></author><author><style face="normal" font="default" size="100%">Herman Van Oyen</style></author><author><style face="normal" font="default" size="100%">Chloé Wyndham-Thomas</style></author><author><style face="normal" font="default" size="100%">Dieter Van Cauteren</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccine</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Contact Tracing</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 09 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">39</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In Belgium, high-risk contacts of an infected person were offered PCR-testing irrespective of their vaccination status. We estimated vaccine effectiveness (VE) against infection and onwards transmission, controlling for previous infections, household-exposure and temporal trends. We included 301,741 tests from 25 January to 24 June 2021. Full-schedule vaccination was associated with significant protection against infection. In addition, mRNA-vaccines reduced onward transmission: VE-estimates increased to &amp;gt;90% when index and contact were fully vaccinated. The small number of viral-vector vaccines included limited interpretability.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">39</style></issue></record></records></xml>